Early use of memantine in the treatment of Lewy body dementia (LBD) is a common type of major neurocognitive disorder (NCD), which is difficult to treat. The use of memantine can be an early treatment strategy. This is illustrated by a case of an 80-year-old patient whose cognition, motor skills and perception disorders reacted favourably to treatment with memantine. The beneficial effect, however, was soon lost after the treatment was discontinued, but reappeared after the medication was reintroduced.status: publishe
The aim of this study is to evaluate memantine effectiveness on behavioural and psychological sympto...
The aim of this study is to evaluate memantine effectiveness on behavioural and psychological sympto...
There are currently no FDA-approved treatments for frontotemporal lobar degeneration (FTLD). The obj...
Objective: To determine the effect of memantine in the treatment of Dementia with Lewy Bodies (DLB)....
OBJECTIVE: This 30-week extension trial was a continuation of the first double-blind randomized cont...
To investigate the effect on survival of treatment with memantine in patients with dementia with Lew...
BACKGROUND: Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are common forms ...
Background: Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are common forms ...
International audiencePrevious studies have suggested that patients with Lewy-body-related dementias...
Memantine is a relatively new drug specially developed for use in moderate-to-severe dementia. It is...
Background: The use of cholinesterase inhibitors to correct the cholinergic deficit in patients with...
Alzheimer's disease (AD) affects the majority of the 35 million people with dementia worldwide. Four...
Early use of memantine in the treatment of Lewy body dementia (LBD) is a common type of major neuroc...
BACKGROUND: The use of cholinesterase inhibitors to correct the cholinergic deficit in patients with...
Aim: To investigate quality of life (QOL) and the effect of memantine treatment in patients with Lew...
The aim of this study is to evaluate memantine effectiveness on behavioural and psychological sympto...
The aim of this study is to evaluate memantine effectiveness on behavioural and psychological sympto...
There are currently no FDA-approved treatments for frontotemporal lobar degeneration (FTLD). The obj...
Objective: To determine the effect of memantine in the treatment of Dementia with Lewy Bodies (DLB)....
OBJECTIVE: This 30-week extension trial was a continuation of the first double-blind randomized cont...
To investigate the effect on survival of treatment with memantine in patients with dementia with Lew...
BACKGROUND: Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are common forms ...
Background: Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are common forms ...
International audiencePrevious studies have suggested that patients with Lewy-body-related dementias...
Memantine is a relatively new drug specially developed for use in moderate-to-severe dementia. It is...
Background: The use of cholinesterase inhibitors to correct the cholinergic deficit in patients with...
Alzheimer's disease (AD) affects the majority of the 35 million people with dementia worldwide. Four...
Early use of memantine in the treatment of Lewy body dementia (LBD) is a common type of major neuroc...
BACKGROUND: The use of cholinesterase inhibitors to correct the cholinergic deficit in patients with...
Aim: To investigate quality of life (QOL) and the effect of memantine treatment in patients with Lew...
The aim of this study is to evaluate memantine effectiveness on behavioural and psychological sympto...
The aim of this study is to evaluate memantine effectiveness on behavioural and psychological sympto...
There are currently no FDA-approved treatments for frontotemporal lobar degeneration (FTLD). The obj...